Combination therapy with mitiglinide and voglibose improves glycemic control in type 2 diabetic patients on hemodialysis

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 2, 2010, Pages 169-176

  Abe, Masanori ^a   Okada, Kazuyoshi ^a   Maruyama, Takashi ^a   Maruyama, Noriaki ^a   Matsumoto, Koichi ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Combination therapy; Hemodialysis; Mitiglinide; Type 2 diabetes; Voglibose

Indexed keywords

GLUCOSE; GLYCOSYLATED ALBUMIN; HEMOGLOBIN A1C; MITIGLINIDE; TRIACYLGLYCEROL; VOGLIBOSE;

ADD ON THERAPY; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERANCE; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMODIALYSIS; HUMAN; INSULIN RESISTANCE; MALE; METABOLIC REGULATION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INOSITOL; ISOINDOLES; MALE; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 76749162763     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903530683     Document Type: Article

References (20)

1. Cao JJ, Hudson M, Jankowski M, et al. Relation of chronic and acute glycemic control on mortality in acute myocardial infarction with diabetes mellitus. Am J Cardiol 2005;96:183-186
2. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Eng J Med 2003;347:383-393 (Pubitemid 36159355)
3. Garber AJ. Attenuating CV risk factors in patients with diabetes: clinical evidence to clinical practice. Diabet Obes Metab 2002;4:S5-12
4. Kassab E, Mc Farlane ST, Sower JR. Vascular complications in diabetes and their prevention. Vasc Med 2001;6:249-255
5. Colwell JA. Vascular thrombosis in type II diabetes mellitus. Diabetes 1993;42:8-11
6. Yale JF. Oral antihyperglycemic agents and renal disease: new agents, new concepts. J Am Soc Nephrol 2005;16:7-10
7. Ohnota H, Koizumi T, Ysutsumi N, et al. Novel rapid- and short-acting hypoglycemic agent, a calcium (2s)-2-benzyl-3-(cis-hexahydro-2- isoindolinylcarbonyl) propionate (KAD-1229) that acts on the sulfonylurea receptor: comparison of effects between KAD-1229 and gliclazide. J Pharmacol Exp Ther 1994;269:489-495
8. Mogami H, Shibata H, Nobusawa R, et al. Inhibition of ATP-senstive K+ channel by a non-sulfonylurea compound KAD-1229 in a pancreatic beta-cell line, MIN 6 cell. Eur J Pharmacol 1994;269:293-298
9. Bakkali-Nadi A, Malaisse-Lagae F, Malaisse WJ. Ionophoretic activity of meglitinide analogues. Diabetes Res 1994;27:61-71
10. Kaku K, Tanaka S, Origasa H, et al. Addition of mitiglinide to pioglitazone monotherapy improves overall glycemic control in Japanese patients with type 2 diabetes: a randomized double blind trial. Endocr J 2009;56:657-664
11. Kaku K, Tanaka S, Orisawa H, et al. Effect of mitiglinide on glycemic control over 52 weeks in Japanese type 2 diabetic patients insufficiently controlled with pioglitazone monotherapy. Endocr J 2009;56:739-746
12. Gao X, The mitiglinide versus nateglinide comparison group. Multicentre, double-blind, randomized study of mitiglinide comapared with nateglinide in type 2 diabetes mellitus patients in China. J Int Med Res 2009;37:812-821
13. Sunaga Y, Gonoi T, Shibasaki T, et al. The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide. Eur J Pharmacol 2001;431:119-125
14. Reimann F, Proks P, Ashcroft FM. Effects of mitiglinide (S 21403) on Kir6.2/SUR1, Kir6.2/SUR2A and Kir6.2/SUR2B types of ATP-sensitive potassium channel. Br J Pharmacol 2001;132:1542-1548
15. Sone H, Ito H, OhashiY Y. Japan Diabetes Complication Study (JDCS) Group: obesity and type 2 diabetes in Japanese patients. Lancet 2003;361:85
16. Abe M, Kikuchi F, Kaizu K, Matsumoto K. Combination therapy of pioglitazone with voglibose improves glycemic control safely and rapidly in type 2 diabetic patients on haemodialysis. Clin Nephrol 2007;68:287-294
17. National Kidney Foundation. KDOQI Clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007;49:S12-154
18. Abe M, Matsumoto K. Glycated hemoglobin or glycated albumin for assessment of glycemic control in hemodialysis patients with diabetes? Nat Clin Pract Nephrol 2008;4:482-483
19. Inaba M, Okuno S, Kumeda Y, et al. Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection. J Am Soc Nephrol 2007;18:896-903
20. Peacock TP, Shihabi ZK, Bleyer AJ, et al. Comparison of glycated albumin and hemoglobin A1c levels in diabetic subjects on hemodialysis. Kidney Int 2008;73:1062-1068